RELATED CONTENT
July 16, 2010 – Lantheus Medical Imaging Inc. this week announced the launch of its ultrasound contrast imaging agent, Definity Vial For (Perflutren Lipid Microsphere) Injectable Suspension, in India.
July 16, 2010 
June 15, 2010 – A new study evaluating the safety of an echocardiography contrast agent found that the agent did not have a significant effect on patients’ pulmonary pressures.
June 15, 2010 
June 8, 2010 - Since August of 2009, Lantheus Medical Imaging has been exploring options to obtain additional molybdenum (Mo-99), which is used to make technetium-99m, an radioisotope used in nuclear medicine imaging.
June 08, 2010 
June 4, 2010 – The first national contract signed for a magnetic resonance imaging angiography (MRA) contrast agent was been signed, making it available to more than 27,000 medical facilities.
June 03, 2010 
When digital electronic devices are first released on the market, they are sold at a premium. Gradually, as their capabilities improve, they become less expensive and more accessible to the masses. Such is the case in molecular imaging with positron emission tomography/computed tomography (PET/CT) and single photon emission computed tomography/computed tomography (SPECT/CT).
May 05, 2010 
March 16, 2010 – Preliminary results from the single-center study suggest that compared to SPECT myocardial perfusion imaging (MPI), flurpiridaz F18 PET MPI has a higher diagnostic specificity for detecting right coronary artery disease and a higher accuracy for evaluating the extent of stress-induced myocardial perfusion abnormalities with coronary angiography as the gold standard.
March 16, 2010 January 25, 2010 - Heart failure is a serious medical condition, in which the heart muscle progressively loses its ability to pump blood, that affects more than five million people in the United States and results in about 1.1 million hospitalizations and 300,000 deaths each year.
January 25, 2010 
January 20, 2010 - The first FDA-cleared contrast imaging agent for use with a magnetic resonance angiography (MRA) indication to evaluate aortoiliac occlusive disease (AIOD) and suspected peripheral vascular disease enters the U.S. market today.
January 20, 2010 
October 8, 2009 – Lantheus Medical Imaging Inc. said two oral presentations featuring gadofosveset trisodium, the first and only FDA cleared blood pool contrast agent for magnetic resonance angiography (MRA), were presented at MRA-Club 09: The 21st Annual International Conference on Magnetic Resonance Angiography.
October 08, 2009 
“Our profession faces one of the most significant crises in its history,” said Michael Graham, M.D., president of the Society of Nuclear Medicine (SNM), regarding the shortage of nuclear medicine radioisotopes.
September 17, 2009